# US 2019/0314467 A1 · Method for preventing and treating liver fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314467 A1
- Document ID: US20190314467A1
- Status: Published application
- Kind: A1
- Application number: 16/470,172
- Filed: 2017-06-19
- Published: 2019-10-17
- Earliest claimed: 2016-12-15
- Assignees: Talengen International Limited
- Applicants: Talengen International Limited
- Inventors: Jinan Li
- Web page: https://patentgrep.com/patent/US20190314467A1

## CPC

- A61K 38/484: {Plasmin (3.4.21.7)}
- A61K 38/48: acting on peptide bonds (3.4)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/04: for non-specific disorders of the connective tissue
- C12Y 304/21007: Plasmin (3.4.21.7), i.e. fibrinolysin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a method for preventing and treating hepatic fibrosis, comprising administering an effective amount of plasminogen to a subject.

## Claims

### Claim 1

A method for preventing or treating hepatic collagen deposition or fibrosis caused by a hepatic tissue injury in a subject, comprising administering an effective amount of plasminogen to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the injury comprises an ischemic reperfusion injury, a drug-induced injury, an immune injury, a chemical-induced injury, an inflammatory injury, an excessive drinking-induced injury, a cancer-induced injury, or a fat deposition-induced injury.

### Claim 3

(canceled)

### Claim 4

A method for preventing or treating hepatic collagen deposition or fibrosis in a subject, comprising administering an effective amount of plasminogen to the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the hepatic collagen deposition or fibrosis is caused or complicated by diabetes mellitus, caused or complicated by atherosclerosis, caused or complicated by hyperlipemia, caused by a drug-induced hepatic injury, or caused by chronic hepatic disease.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 5)

The method of claim 5, wherein the hyperlipemia comprises one or more selected from: an elevated blood triglyceride level, an elevated total blood cholesterol level, increased blood low-density lipoprotein, and increased blood very low-density lipoprotein.

### Claim 9

(canceled)

### Claim 10 (depends on 5)

The method of claim 5, wherein the drug is a hepatotoxic drug.

### Claim 11 (depends on 10)

The method of claim 10, wherein the drug comprises a chemotherapeutic drug, an antibiotic drug, a hypolipidemic drug, an antihypertensive drug, or a hypoglycemic drug.

### Claim 12

A method for preventing or treating alcoholic hepatic collagen deposition or fibrosis or non-alcoholic hepatic collagen deposition or fibrosis in a subject, comprising administering an effective amount of plasminogen to the subject.

### Claim at position 13

-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the plasminogen is administered in combination with one or more other drugs or therapeutic means.

### Claim 18 (depends on 17)

The method of claim 17, wherein the one or more other drugs comprise: a hypolipidemic drug, an anti-platelet drug, an antihypertensive drug, a vasodilator, a hypoglycemic drug, an anticoagulant drug, a thrombolytic drug, a hepatoprotective drug, an anti-fibrosis drug, an anti-arrhythmia drug, a cardiotonic drug, a diuretic drug, an anti-tumor drug, a radiotherapeutic or chemotherapeutic drug, an inflammatory regulatory drug, an immunomodulatory drug, an antiviral drug, or an antibiotic.

### Claim 19 (depends on 1)

The method of claim 1, wherein the plasminogen has at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQ ID No. 2, and still has the plasminogen activity.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the plasminogen is a protein that comprises a plasminogen active fragment and still has the plasminogen activity.

### Claim 22 (depends on 1)

The method of claim 1, wherein the plasminogen is selected from Glu-plasminogen, Lys-plasminogen, mini-plasminogen, micro-plasminogen, delta-plasminogen or their variants that retain the plasminogen activity.

### Claim 23 (depends on 1)

The method of claim 1, wherein the plasminogen is a natural or synthetic human plasminogen, or a variant or fragment thereof that still retains the plasminogen activity.

### Claim at position 21

-37. (canceled)

### Claim 38 (depends on 5)

The method of claim 5, wherein the chronic hepatic disease is viral hepatitis.

### Claim 39 (depends on 1)

The method of claim 1, wherein the plasminogen is administered to the subject at a dosage of 1-100 mg/kg, 1-50 mg/kg, or 1-10 mg/kg, daily, every other day, or weekly.

### Claim 40 (depends on 39)

The method of claim 39, wherein the administration of the plasminogen is preferably repeated at least once.

### Claim 41 (depends on 39)

The method of claim 39, wherein the plasminogen is preferably administered at least daily.
